FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979803485> ?p ?o ?g. }

• W1979803485 endingPage "653" @default.
• W1979803485 startingPage "645" @default.
• W1979803485 abstract "A prostate brachytherapy program was initiated in 1990, when comparatively little was known of the relative importance of disease- and treatment-related factors on outcome. Patients treated during the first 6 years of the program were analyzed to determine the value of patient selection and implant quality on biochemical control.We treated 243 patients with clinically localized prostate cancer with radioactive seed implantation and underwent 1-month CT-based dosimetric analysis. Follow-up ranged from 61 to 135 months (median 75). The Gleason score was < or =6 in 78% (n = 189), 7 in 14% (n = 35), and 8-10 in 8% (n = 19). The initial prostate-specific antigen (PSA) level was < or =10 ng/mL in 61% (n = 149), 10.1-20 ng/mL in 26% (n = 63), and >20 ng/mL in 13% (n = 31). The disease stage was T2a or less in 49% (n = 120), and Stage T2b-T2c in 51% (n = 123). A real-time ultrasound-guided technique was used with (125)I (n = 138) and (103)Pd (n = 105) isotopes. No patient underwent external beam radiotherapy as part of their primary treatment. Of the 243 patients, 60% also received hormonal ablation for at least 3 months before and 2-3 months after seed implantation. All patients included underwent a 1-month CT-based dosimetric analysis. The implant dose was defined as the dose delivered to 90% of the prostate volume on postimplant dosimetry (D(90)). On the basis of prior dose-response analyses, patients were retrospectively grouped into optimal D(90) ((125)I > or =140 Gy Task Group 43 or (103)Pd >/=100 Gy) and suboptimal D(90) ( (125)I <140 Gy or (103)Pd <100 Gy) dose groups. Biochemical failure was defined using the American Society for Therapeutic Radiology Oncology definition.Disease-related factors, including initial PSA level, Gleason score, and stage, were significant predictors of biochemical failure. The actuarial 8-year freedom from biochemical failure (bFFF) rate was 80% for those with a PSA level < or =10 ng/mL, 86% for PSA 10.1-20 ng/mL, and 45% for PSA >20 ng/mL (p = 0.0019). Patients with a Gleason score of < or =6 had an 8-year bFFF rate of 81% vs. 67% for those with Gleason score 7 and 53% for those with Gleason score 8-10 (p = 0.0003). Patients with Stage T2a or less had an 8-year bFFF rate of 85% compared with 69% for those with Stage T2b-T2c (p = 0.013). The 8-year bFFF rate was 88% for low-risk patients (Stage T2a or less, Gleason score < or =6, and initial PSA level < or =10 ng/mL; n = 75), 81% for moderate-risk patients (Stage T2b or Gleason score 7 or initial PSA level >10.1-20 ng/mL; n = 70), and 65% for high-risk patients (two or more moderate-risk features or Gleason score > or =8 or initial PSA level >20 ng/mL; n = 98; p = 0.0009). Patients with optimal dose implants (n = 145) had an 8-year bFFF rate of 82% compared with 68% for those with suboptimal dose implants (n = 98; p = 0.007). Hormonal therapy did not significantly affect biochemical failure (p = 0.27). In multivariate analysis, the statistically significant variables included initial PSA level (p <0.0001), Gleason score (p = 0.024), and dose group (p = 0.046). Because our current practice limits implantation alone to low-risk patients, an analysis of this subgroup was undertaken to validate the importance of dose. In the optimal dose group, low-risk patients had an 8-year bFFF rate of 94% vs. 75% for the low-risk patients in the suboptimal dose group (p = 0.02).With minimal follow-up of 5 years, these data continue to support the use of implantation alone in low-risk prostate cancer patients and demonstrate the importance of implant quality (dose) in achieving optimal outcomes. Low-risk patients who receive an optimal dose implant have a 94% bFFF rate at 8 years." @default.
• W1979803485 created "2016-06-24" @default.
• W1979803485 creator A5008857530 @default.
• W1979803485 creator A5012386908 @default.
• W1979803485 creator A5049069950 @default.
• W1979803485 date "2003-11-01" @default.
• W1979803485 modified "2023-09-24" @default.
• W1979803485 title "Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality" @default.
• W1979803485 cites W1480176913 @default.
• W1979803485 cites W1996906268 @default.
• W1979803485 cites W2008488596 @default.
• W1979803485 cites W2023104730 @default.
• W1979803485 cites W2026118965 @default.
• W1979803485 cites W2026580144 @default.
• W1979803485 cites W2035999871 @default.
• W1979803485 cites W2046548861 @default.
• W1979803485 cites W2047513095 @default.
• W1979803485 cites W2049259118 @default.
• W1979803485 cites W2053580929 @default.
• W1979803485 cites W2064057265 @default.
• W1979803485 cites W2065722777 @default.
• W1979803485 cites W2066197900 @default.
• W1979803485 cites W2068115015 @default.
• W1979803485 cites W2076626488 @default.
• W1979803485 cites W2082943541 @default.
• W1979803485 cites W2097771960 @default.
• W1979803485 cites W2117792530 @default.
• W1979803485 cites W2118157857 @default.
• W1979803485 cites W2121495561 @default.
• W1979803485 cites W2126645707 @default.
• W1979803485 cites W2129063409 @default.
• W1979803485 cites W2140680429 @default.
• W1979803485 cites W2144629663 @default.
• W1979803485 cites W2145567281 @default.
• W1979803485 cites W2148050247 @default.
• W1979803485 cites W2165488001 @default.
• W1979803485 cites W2416600156 @default.
• W1979803485 cites W4320801101 @default.
• W1979803485 doi "https://doi.org/10.1016/s0360-3016(03)00627-8" @default.
• W1979803485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14529768" @default.
• W1979803485 hasPublicationYear "2003" @default.
• W1979803485 type Work @default.
• W1979803485 sameAs 1979803485 @default.
• W1979803485 citedByCount "143" @default.
• W1979803485 countsByYear W19798034852012 @default.
• W1979803485 countsByYear W19798034852013 @default.
• W1979803485 countsByYear W19798034852014 @default.
• W1979803485 countsByYear W19798034852015 @default.
• W1979803485 countsByYear W19798034852016 @default.
• W1979803485 countsByYear W19798034852017 @default.
• W1979803485 countsByYear W19798034852018 @default.
• W1979803485 countsByYear W19798034852019 @default.
• W1979803485 countsByYear W19798034852021 @default.
• W1979803485 countsByYear W19798034852022 @default.
• W1979803485 crossrefType "journal-article" @default.
• W1979803485 hasAuthorship W1979803485A5008857530 @default.
• W1979803485 hasAuthorship W1979803485A5012386908 @default.
• W1979803485 hasAuthorship W1979803485A5049069950 @default.
• W1979803485 hasConcept C121608353 @default.
• W1979803485 hasConcept C126322002 @default.
• W1979803485 hasConcept C126894567 @default.
• W1979803485 hasConcept C141071460 @default.
• W1979803485 hasConcept C146357865 @default.
• W1979803485 hasConcept C151730666 @default.
• W1979803485 hasConcept C2775908122 @default.
• W1979803485 hasConcept C2776235491 @default.
• W1979803485 hasConcept C2777416452 @default.
• W1979803485 hasConcept C2778311097 @default.
• W1979803485 hasConcept C2778648096 @default.
• W1979803485 hasConcept C2780192828 @default.
• W1979803485 hasConcept C2781406297 @default.
• W1979803485 hasConcept C2781411149 @default.
• W1979803485 hasConcept C2989005 @default.
• W1979803485 hasConcept C509974204 @default.
• W1979803485 hasConcept C71924100 @default.
• W1979803485 hasConcept C75088862 @default.
• W1979803485 hasConcept C86803240 @default.
• W1979803485 hasConceptScore W1979803485C121608353 @default.
• W1979803485 hasConceptScore W1979803485C126322002 @default.
• W1979803485 hasConceptScore W1979803485C126894567 @default.
• W1979803485 hasConceptScore W1979803485C141071460 @default.
• W1979803485 hasConceptScore W1979803485C146357865 @default.
• W1979803485 hasConceptScore W1979803485C151730666 @default.
• W1979803485 hasConceptScore W1979803485C2775908122 @default.
• W1979803485 hasConceptScore W1979803485C2776235491 @default.
• W1979803485 hasConceptScore W1979803485C2777416452 @default.
• W1979803485 hasConceptScore W1979803485C2778311097 @default.
• W1979803485 hasConceptScore W1979803485C2778648096 @default.
• W1979803485 hasConceptScore W1979803485C2780192828 @default.
• W1979803485 hasConceptScore W1979803485C2781406297 @default.
• W1979803485 hasConceptScore W1979803485C2781411149 @default.
• W1979803485 hasConceptScore W1979803485C2989005 @default.
• W1979803485 hasConceptScore W1979803485C509974204 @default.
• W1979803485 hasConceptScore W1979803485C71924100 @default.
• W1979803485 hasConceptScore W1979803485C75088862 @default.
• W1979803485 hasConceptScore W1979803485C86803240 @default.
• W1979803485 hasIssue "3" @default.
• W1979803485 hasLocation W19798034851 @default.

• next